ABSTRACT
OBJECTIVE: To retrospectively study the clinical efficacy and safety of sulbactam sodium in treatment of extensively drug resistant Acinetobacter baumannii(XDRAB) infection. METHODS: Collect cases of XDRAB infection treated with sulbactam Sodium in our hospital from January 2014 to January 2016. Basic information of patients, infection sites, therapeutic strategies, drug combination, clinical outcomes and adverse reactions were analyzed retrospectively. RESULTS: A total of 7 cases were collected, including 4 cases of pulmonary infection, 2 cases of intracranial infection, 1 case of abdominal infection, therapeutic strategies for sulbactam sodium-based combination therapy. The total mortality rate was 42.8%; 1 case showed adverse drug reactions may correlated with sulbactam sodium. CONCLUSION: Mortality associated with XDRAB infection is high, and the clinical outcome is associated with host factors, because this article included in the number of cases is less, so difficult to evaluate the effectiveness of sulbactam sodium. Sulbactam sodium can be associated with other antimicrobial drugs for the treatment of XDRAB infection and provided more choices.
ABSTRACT
Objective To investigate the bacteriostatic effect of 4 kinds of traditional Chinese herbal medicine on extensively drug‐resistant A .baumannii(XDRAB) bacteriostatic effect ,find a new way for the clinical treatment of the XDRAB infection .Meth‐ods The minimal inhibitory concentrations(MICs) of scutellaria ,forsythia ,rhizoma coptidis ,honeysuckle were determined by using broth two‐fold dilution method .Results The mean values of MICs of scutellaria ,forsythia ,rhizoma coptidis ,honeysuckle were 30 .99 ,187 .50 ,27 .61 and 75 .00 mg/mL ,respectively .Among the 4 kinds of traditional Chinese herbal medicines ,rhizoma coptidis got the strongest antimicrobial effect strongest inhibitory effect .There was no significant difference in the inhibitory effect of the strains collected from local or nonlocal(P>0 .05) .Conclusion The 4 kinds of Chinese herbal medicine had in vitro antibacterial ac‐tivity to XDRAB in different degree.
ABSTRACT
Objective To observe the clinical efficacy and adverse reactions of tigecycline in treatment of health-care-associated pneumonia (HAP ) caused by extensively drug-resistant Acinetobacter baumannii (XDRAB ). Methods Clinical data of patients who used tigecycline for the treatment of XDRAB HAP in intensive care units of a hospital from March 2013 to June 2014 were retrospectively analyzed.Results XDRAB isolated from 31 patients with HAP were all sensitive to tigecycline,the resistance rates to carbapenems and sulbactams (including cefopera-zone-sulbactam,SCF)were all 100%,17 cases (54.84%)were mixed infection.Combined use rates of tigecycline and SCF were 85.71 %(12/14)in respiratory intensive care unit(RICU)and 47.06%(8/17)in general intensive care unit(GICU).Of 31 patients,the cure rate,effective rate,bacterial clearance rate,and antimicrobial adverse reac-tion rate were 29.03%,45.16%,61 .29%,and 16.13% respectively,no serious adverse drug reactions occurred. In RICU group and GICU group,the cure rates were 42.86% and 17.65% respectively,effective rates were 71 .43% and 23.53% respectively,and bacterial clearance rates were 78.57 % and 47.06% respectively,difference in effective rate between two groups was significant (P <0.05).Among patients receiving combination of tigecycline and SCF as well as not receiving combined SCF,the cure rates were 35.00% and 18.18% respectively,effective rates were 60.00% and 18.18% respectively,and bacterial clearance rates were 65.00% and 54.55% respectively, difference in effective rate between two groups was significant (P <0.05).Conclusion Tigecycline has a good clini-cal efficacy and little adverse reaction in treating XDRAB HAP;tigecycline combined with SCF is a good choice.